Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.74−0.15 (-0.79%)
Close on Nov 13, 2026Market cap $3.00BP/E –Yield –
Denali Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Denali Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $400.72M, down 3.9% year over year. For fiscal 2025 it was $418.78M, up 5.6% from the year before. The highest annual figure on record is $423.88M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.78M | +5.6% |
| FY2024 | Dec 31, 2024 | $396.44M | -6.5% |
| FY2023 | Dec 31, 2023 | $423.88M | +18.2% |
| FY2022 | Dec 31, 2022 | $358.73M | +35.2% |
| FY2021 | Dec 31, 2021 | $265.35M | +24.8% |
| FY2020 | Dec 31, 2020 | $212.62M | +9.9% |
| FY2019 | Dec 31, 2019 | $193.38M | +35.1% |
| FY2018 | Dec 31, 2018 | $143.18M | +92.3% |
| FY2017 | Dec 31, 2017 | $74.46M | -1.6% |
| FY2016 | Dec 31, 2016 | $75.70M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $97.02M | -5.5% |
| Q1 FY2026 | Mar 31, 2026 | $103.85M | -10.7% |
| Q4 FY2025 | Dec 31, 2025 | $97.91M | -1.9% |
| Q3 FY2025 | Sep 30, 2025 | $101.95M | +3.8% |
| Q2 FY2025 | Jun 30, 2025 | $102.70M | +12.4% |
| Q1 FY2025 | Mar 31, 2025 | $116.23M | +8.6% |
| Q4 FY2024 | Dec 31, 2024 | $99.79M | -7.4% |
| Q3 FY2024 | Sep 30, 2024 | $98.24M | +9.5% |
| Q2 FY2024 | Jun 30, 2024 | $91.40M | -6.3% |
| Q1 FY2024 | Mar 31, 2024 | $107.02M | -16.9% |
| Q4 FY2023 | Dec 31, 2023 | $107.80M | +17.0% |
| Q3 FY2023 | Sep 30, 2023 | $89.74M | +2.2% |
| Q2 FY2023 | Jun 30, 2023 | $97.52M | +5.2% |
| Q1 FY2023 | Mar 31, 2023 | $128.82M | +49.6% |
| Q4 FY2022 | Dec 31, 2022 | $92.11M | +35.7% |
| Q3 FY2022 | Sep 30, 2022 | $87.79M | +22.7% |
| Q2 FY2022 | Jun 30, 2022 | $92.74M | +41.1% |
| Q1 FY2022 | Mar 31, 2022 | $86.10M | +43.0% |
| Q4 FY2021 | Dec 31, 2021 | $67.88M | +24.0% |
| Q3 FY2021 | Sep 30, 2021 | $71.56M | +33.2% |
| Q2 FY2021 | Jun 30, 2021 | $65.71M | +23.6% |
| Q1 FY2021 | Mar 31, 2021 | $60.21M | +18.0% |
| Q4 FY2020 | Dec 31, 2020 | $54.74M | +6.2% |
| Q3 FY2020 | Sep 30, 2020 | $53.70M | +2.2% |
| Q2 FY2020 | Jun 30, 2020 | $53.15M | +2.4% |
| Q1 FY2020 | Mar 31, 2020 | $51.02M | +36.4% |
| Q4 FY2019 | Dec 31, 2019 | $51.55M | +29.2% |
| Q3 FY2019 | Sep 30, 2019 | $52.54M | +73.3% |
| Q2 FY2019 | Jun 30, 2019 | $51.88M | -0.5% |
| Q1 FY2019 | Mar 31, 2019 | $37.40M | +79.7% |
| Q4 FY2018 | Dec 31, 2018 | $39.91M | +116.1% |
| Q3 FY2018 | Sep 30, 2018 | $30.32M | +63.8% |
| Q2 FY2018 | Jun 30, 2018 | $52.13M | +174.3% |
| Q1 FY2018 | Mar 31, 2018 | $20.82M | +12.7% |
| Q4 FY2017 | Dec 31, 2017 | $18.47M | – |
| Q3 FY2017 | Sep 30, 2017 | $18.52M | – |
| Q2 FY2017 | Jun 30, 2017 | $19.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $18.47M | – |
See a number that looks wrong?